Improving Safety in Phase I Trials - Planning Your Early Phase Development?

Posted:
24
April 2007

Join Richmond Pharmacology at Europe's leading Exploratory Clinical Development Congress13-16 May 2008, Earls Court Conference Centre, LondonAs the UK's largest Early Phase CRO, uniquely based in 2 acute NHS teaching hospitals, Richmond Pharmacology Ltd is proud to be an Associate Sponsor of the upcoming Exploratory Clinical Development Congress.Dr. Jorg Taubel, Managing Director of RPL, will be presenting on Day One, 14th May at 10.30am, on "Managing Risk in Early Development" and as an experienced trialist will be part of the panel discussion on "Improving the Safety of Phase I trials".We are delighted to be able to offer you a 15% discount on any delegate packages to attend this conference - please see below for details.In 2008, early clinical development remains at a critical stage. The transition to First In Man has crucial regulatory, scientific and operational issues that need to be confronted head on in order to avoid high costs and high profile product failures. Safety concerns continue to dominate and following recommendations from the ESG Working Group, the ABPI has revised its guidelines for Phase I trials.The second Exploratory Clinical Development Congress will address the critical issues in achieving seamless First In Man studies and will also provide advice on how to conduct effective studies that allow you to make the right decision early on in clinical development.Topics to be addressed at the 2008 Congress include:

  • Improving the safety of Phase I Trials - Where are we now?
  • Creating a smooth transition between preclinical and first use in man
  • Enhanced Phase I strategies
  • Managing risk in early development
  • Choosing the right dosage form
  • Biomarkers in early development
  • QT in Phase I
  • Protocol design for Phase I trials
  • The role of experimental medicine
  • Translational medicine and the rational design of exploratory studies

15% discount on attendance at this conference - If you wish to accept this offer, please contact Health Network Communications directly on: +44(0)20 7608 7056 or email: kwilliams@healthnetworkcommunications.com, quoting Richmond Pharmacology.We will be exhibiting on Stand 2 and would like to extend a warm invitation to join us on the stand to discuss your upcoming Early Phase outsourcing requirements.We look forward to meeting you at the Congress,Best regards,Dr. Jorg Taubel MFPM, MDManaging Director

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more